Darzynkiewicz Z, Carter S P, Mikulski S M, Ardelt W J, Shogen K
Sloan-Kettering Institute for Cancer Research, Walker Laboratory, Rye, NY 10580.
Cell Tissue Kinet. 1988 May;21(3):169-82. doi: 10.1111/j.1365-2184.1988.tb00855.x.
P-30 Protein is a novel protein, of molecular weight approximately 15 KD, obtained from the extract of a vertebrate tissue showing in vivo antitumour activity. Cytostatic and cytotoxic effects of this product in its purified form (P-30 Protein) or in partially purified extracts (Pannon) were studied in vitro on human leukaemic HL-60, human submaxillary carcinoma A-253, human colon adenocarcinoma Colo 320 CM and murine erythroleukaemia (Friend leukaemia) cell lines. Of these cells, HL-60, A-253 and Colo 320 CM were sensitive and Friend leukaemia resistant to this agent. The effects were time- and concentration-dependent. During the initial 24-48 h of treatment, a slowdown in cell proliferation was apparent but cell death was not extensive. After 24-48 h, there was a reduction in the proportion of cells in S phase of the cell cycle and the cells became preferentially arrested in G1 phase. The G1 cells showed high heterogeneity with respect to RNA content and some cells were characterized by very low RNA content. Progressive cell death occurred in cultures maintained with Pannon for up to 7 d in proportion to its concentration. Reductions of 50 and 90% in clonogenicity of A-253 cells were observed during their growth in the presence of 0.13 and 1.5 micrograms/ml of this protein, respectively. Exponentially growing cells were more sensitive to Pannon compared with cells from confluent cultures. Colonies of A-253 cells growing in the presence of Pannon were much smaller in size compared with control colonies, indicating that the rate of proliferation of clonogens is reduced by this agent. It appears that P-30 Protein induces cytostatic effects via modulation of cell transition to quiescence or differentiation. The mechanism of its cytotoxic activity is unclear.
P - 30蛋白是一种新型蛋白质,分子量约为15千道尔顿,从具有体内抗肿瘤活性的脊椎动物组织提取物中获得。对该产品的纯化形式(P - 30蛋白)或部分纯化提取物(潘农)在体外对人白血病HL - 60、人下颌腺癌A - 253、人结肠腺癌Colo 320 CM和小鼠红白血病(弗瑞德白血病)细胞系的细胞生长抑制和细胞毒性作用进行了研究。在这些细胞中,HL - 60、A - 253和Colo 320 CM对该药物敏感,而弗瑞德白血病细胞对此耐药。这些作用具有时间和浓度依赖性。在治疗的最初24 - 48小时内,细胞增殖明显减缓,但细胞死亡并不广泛。24 - 48小时后,细胞周期S期的细胞比例降低,细胞优先停滞在G1期。G1期细胞在RNA含量方面表现出高度异质性,一些细胞的特征是RNA含量非常低。在用潘农维持培养长达7天的培养物中,细胞逐渐死亡,且与浓度成正比。在分别存在0.13和1.5微克/毫升这种蛋白质的情况下,观察到A - 253细胞的克隆形成能力分别降低了50%和90%。与汇合培养的细胞相比,指数生长的细胞对潘农更敏感。在潘农存在下生长的A - 253细胞集落与对照集落相比要小得多,这表明该药物降低了克隆原细胞的增殖速率。似乎P - 30蛋白通过调节细胞向静止或分化的转变来诱导细胞生长抑制作用。其细胞毒性活性的机制尚不清楚。